Skip to Content

Orvaten (midodrine) Disease Interactions

There are 4 disease interactions with Orvaten (midodrine):

Major

Midodrine (Includes Orvaten) ↔ hypertension/diabetes

Severe Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus, Hypertension

Midodrine can cause marked elevation of supine blood pressure (BP>200 mmHg systolic) and should not be used in patients with persistent and excessive supine hypertension. Systolic elevations of this degree are most likely to be observed in patients with relatively elevated pre-treatment systolic blood pressures (mean 170 mmHg). There is no experience in patients with initial supine systolic pressure above 180 mmHg, as those patients were excluded from the clinical trials. Use of midodrine in such patients is not recommended. Additionally, care should be taken when using this agent in orthostatic hypotensive patients who are also diabetic. Supine and sitting hypertension should be evaluated at the beginning of therapy, and blood pressure (supine, sitting, and orthostatic) should be monitored regularly.

Major

Midodrine (Includes Orvaten) ↔ hypertensive effects

Severe Potential Hazard, High plausibility. Applies to: Pheochromocytoma, Thyrotoxicosis, Heart Disease

The use of midodrine is contraindicated in patients with severe organic heart disease, pheochromocytoma, or thyrotoxicosis.

References

  1. "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Major

Midodrine (Includes Orvaten) ↔ renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Urinary Retention, Renal Dysfunction

The use of midodrine is contraindicated in patients with acute renal disease or urinary retention/obstruction disorder. Midodrine is primarily eliminated by the kidney as desglymidodrine (active metabolite). The serum concentration of midodrine is expected to be increased in patients with renal impairment. Desglymidodrine induces urinary retention by increasing bladder neck tone. Therapy with midodrine should be administered cautiously and initiated at 2.5 mg doses in patients with compromised renal function. Clinical monitoring of renal function prior to initiation of therapy and subsequently as appropriate and blood pressure (supine, sitting, and orthostatic) is recommended. Midodrine is removed by dialysis.

References

  1. "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
Moderate

Midodrine (Includes Orvaten) ↔ hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Midodrine, a prodrug, undergoes bioactivation in a variety of tissues to desglymidodrine, an alpha-1 agonist. The liver functions in the metabolism of midodrine and desglymidodrine. The pharmacokinetic disposition of midodrine has not been studied in patients with hepatic impairment. Therapy with midodrine should be administered cautiously in patients with compromised hepatic function. Clinical monitoring of hepatic function prior to initiation of therapy.

References

  1. "Product Information. ProAmatine (midodrine)." Roberts Pharmaceutical Corporation, Eatontown, NJ.

Orvaten (midodrine) drug interactions

There are 522 drug interactions with Orvaten (midodrine)

Orvaten (midodrine) alcohol/food interactions

There is 1 alcohol/food interaction with Orvaten (midodrine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide